Dual Targeting Nanobody Bispecific for Enhanced Immunotherapy in Colorectal Cancer
VHH-P530 is a humanized nanobody-based bispecific antibody designed to target both CD274 molecule (CD274) and claudin 18 (CLDN18), two clinically relevant antigens in oncology. Currently in the Biological Testing stage of development, VHH-P530 offers a promising approach for the treatment of colorectal cancer. By combining distinct targeting domains within a compact format, this program aims to overcome resistance mechanisms and address critical unmet needs in colorectal cancer therapeutics. The dual specificity of VHH-P530 is designed to enhance both direct tumor cell targeting and modulation of the immune microenvironment.
| Candidate | VHH-P530 |
| Target | CD274 molecule (CD274) claudin 18 (CLDN18) |
| Modality | humanized bispecific VHH |
| Indication | Colorectal Cancer |
Licensing Opportunity
VHH-P530 is available for out-licensing and strategic partnerships. We welcome collaborations with industry partners to further advance the clinical development and commercialization of this promising colorectal cancer immunotherapeutic.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P530 |
Modality
VHH-P530 utilizes a bispecific nanobody format, incorporating two identical polypeptide chains fused in sequence: an anti-human CLDN18.2 nanobody, a flexible (G4S)3 linker, and an anti-human CD274 nanobody, followed by an IgG1 hinge and Fc. Expressed in ExpiCHO cells, this modality leverages the small size and single-domain nature of nanobodies, enabling superior tumor tissue penetration and the ability to engage targets that may be less accessible to conventional antibodies. The multi-specific architecture is designed to simultaneously modulate the tumor microenvironment and directly interact with colorectal cancer cells, while benefiting from the stability and developability of the IgG1 Fc domain.
Target
CD274 and CLDN18 are well-validated molecular targets in oncology. CD274, an immune checkpoint ligand, modulates T cell activity and is often upregulated in tumor cells and the tumor microenvironment, contributing to immune escape. CLDN18 is a tight junction protein predominantly expressed in select epithelial tissues and is notably overexpressed in various malignancies, including subsets of colorectal cancer. Therapeutically, the combinatorial targeting of CD274 and CLDN18 holds strategic value for colorectal cancer by directly addressing tumor immune evasion (via CD274) and tumor cell-specificity (via CLDN18). VHH-P530’s capacity to simultaneously engage both CD274 and CLDN18 enables a multifaceted attack on the tumor, reinforcing its promise as a next-generation biologic in colorectal cancer management.
Mechanism of Action
VHH-P530 exerts its effect through simultaneous recognition of CD274 and CLDN18. By binding to CD274 on tumor and immune cells, VHH-P530 inhibits checkpoint interactions, facilitating T cell activation and enhancing antitumor immune responses. Concurrent binding to CLDN18, which is upregulated on colorectal cancer cells, enables direct targeting of tumor cells. The bispecific design amplifies the potential to combine immune checkpoint blockade and selective tumor cell recognition within a single molecule. Furthermore, the nanobody platform offers future flexibility for derivatization, enabling applications as antibody-drug conjugates or tri-specific constructs, thus expanding its therapeutic reach beyond initial indications.
Colorectal Cancer
Colorectal cancer is one of the most common malignancies worldwide, with significant morbidity and mortality. Epidemiological data highlight its high incidence in both developed and developing countries. Standard therapies for colorectal cancer include surgical resection, chemotherapy, radiation, and targeted agents. Yet, despite these interventions, relapse and metastatic progression remain frequent challenges, especially in advanced-stage disease. Current treatment approaches are often limited by resistance, toxicity, and incomplete responses, underscoring the need for novel therapeutics. Immunotherapies addressing the tumor microenvironment and specific tumor antigens have gained increasing attention. VHH-P530 offers a unique therapeutic proposition by integrating immune checkpoint inhibition (via CD274) with precise tumor cell targeting (via CLDN18), positioning it to address unmet needs and improve outcomes for patients with colorectal cancer.